Claims for Patent: 6,210,667

Summary for Patent: 6,210,667

Title:	Bacterial fibrin-dependent plasminogen activator
Abstract:	A pharmaceutical composition in a preferred embodiment comprises an isolated bacterial protein that induces fibrin-dependent plasminogen activation, and methods for dissolving blood clots in a subject use such a composition. Embodiments also include a nucleic acid encoding such a bacterial protein, a nucleic acid encoding such a bacterial protein as a fusion to another protein, an expression vector with the nucleic acid, and a host cell transformed with the expression vector.
Inventor(s):	Guy L. Reed
Assignee:
Application Number:	US09/211,542
Patent Claims:	1. A composition for dissolving blood clots in a subject, comprising an isolated genetically modified substantially pure streptokinase in a pharmaceutically acceptable carrier, the streptokinase capable under physiological conditions of plasminogen activation in the presence but not the absence of fibrin, and that induces, under physiological conditions, dissolution of fibrin in a clot while sparing fibrinogen in the plasma, wherein the modification of streptokinase is a mutational alteration such that the amino terminus is selected from the group consisting of amino acid residues 24, 59, 60, 65, 144, and 149 of SEQ ID NO: 6. 2. An effective dose of a composition according to claim 1. 3. A composition according to claim 1, wherein activation of plasminogen is at least fifty-fold greater in the presence of fibrin than in the absence of fibrin. 4. A composition according to claim 3, wherein activation of plasminogen is at least hundred-fold greater in the presence than in the absence of fibrin. 5. A composition according to claim 1, wherein the genetically modified streptokinase is produced as a fusion protein. 6. A composition according to claim 5, wherein the protein is produced as a fusion having at its amino terminus the maltose binding protein. 7. A composition according to claim 1 having a carboxy terminus selected from the group consisting of amino acid residues 293, 386 and 414. 8. A composition comprising an effective dose of an isolated genetically modified substantially pure streptokinase, the modification being deletion of amino acid residues in the amino terminus, wherein the modified streptokinase is a fibrin-dependent plasminogen activator having an amino terminus selected from the group consisting of amino acid residues 24, 59, 60, 65, 144, and 149 of SEQ ID NO: 6, and that induces, under physiological conditions, dissolution of fibrin in a clot while sparing fibrinogen in the plasma. 9. A recombinantly produced substantially pure streptokinase having a deletion of the amino terminus of SEQ ID NO: 6, wherein the deletion extends from residue 1 through residue 23 to residue 148, such that the amino terminus of the streptokinase is selected from the group consisting of any of residues 24 through 149 of SEQ ID NO: 6, the modified streptokinase capable under physiological conditions of activating plasminogen only in the presence of a clot, while sparing fibrinogen in the plasma. 10. A recombinantly produced modified streptokinase according to claim 9, wherein the carboxy terminus is selected from the group consisting of residues 293, 386 and 414 of SEQ ID NO: 6. 11. An effective dose of a recombinantly produced modified streptokinase according to claim 9, wherein antigenic residues are genetically deleted to diminish reactivity with antibodies in a human subject.

Details for Patent 6,210,667

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biomarin Pharmaceutical Inc.	ALDURAZYME	laronidase	Injection	125058	April 30, 2003		2018-12-15